Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial

Trial Profile

Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Cytarabine (Primary) ; Folinic acid (Primary) ; Lenalidomide (Primary) ; Methotrexate (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LeMLAR
  • Most Recent Events

    • 02 Dec 2014 Planned End Date changed from 1 Aug 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 22 Nov 2014 Planned number of patients changed from 44 to 56 as reported by European Clinical Trials Database record.
    • 13 Feb 2013 New source identified and integrated (ClinicalTrials.gov record, NCT01788189).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top